All In Biotech

Drug Trial Radar · NCT07107256

Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 246 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

246

Actual

Start

Sep 25, 2025

Primary completion

Mar 2027

Study completion Sep 2027

Sponsor

Sponsor type
Industry
First posted
Aug 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TQC2731 injection is a humanized monoclonal antibody that targets Thymic Stromal Lymphopoietin (TSLP), blocks the TSLP pathway, and inhibits the production of downstream cytokines, thereby exerting anti-inflammatory effects. The purpose of this study is to evaluate the efficacy and safety of TQC2731 injection in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Conditions

  • Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Interventions

  • TQC2731 injectionDrug

    TQC2731 injection is a humanized monoclonal antibody that targets TSLP, blocks the TSLP signaling pathway, inhibits the production of downstream cytokines, and exerts anti-inflammatory effects.

  • Placebo of TQC2731Drug

    TQC2731 injection is a humanized monoclonal antibody that targets TSLP, blocks the TSLP signaling pathway, inhibits the production of downstream cytokines, and exerts anti-inflammatory effects.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Nasal Polyp Score (NPS)Time frame: From baseline to Week 24
  2. Nasal Congestion Score (NCS)Time frame: From baseline to Week 24
  3. Change in nasal polyp score (NPS) from baselineTime frame: From baseline to Week 24
  4. Change from baseline in Nasal Congestion Score (NCS)Time frame: From baseline to Week 24

Locations

60 sites in 1 country. Site status is shown where the registry gives one.

  • Zhongda Hosiptal Southeast University

    Fuyang, Anhui, China

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Peking University People'S Hospital

    Beijing, Beijing Municipality, China

  • Beijing youan hospital,capital medical university

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • The 940th Hospital of Joint Logistics Support force of Chinese People 's Liberation Army

    Lanzhou, Gansu, China

  • The Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Shenzhen Second People'S Hospital

    Shenzhen, Guangdong, China

  • Liuzhou People's Hospital

    Liuzhou, Guangxi, China

  • Cangzhou Central Hospital

    Cangzhou, Hebei, China

  • Hebei Petro China Central Hospital

    Langfang, Hebei, China

  • Hebei Medical University Third Hospital

    Shijiazhuang, Hebei, China

  • The First Affiliated Hospital of Hebei North University

    Zhangjiakou, Hebei, China

  • Daqing People's Hospital

    Daqing, Heilongjiang, China

  • Henan Provincial People'S Hospital

    Zhengzhou, Henan, China

  • Jingzhou Central Hospital

    Jingzhou, Hubei, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • The First People's Hospital of Changde City

    Changde, Hunan, China

  • People's Hospital of Hunan Province

    Changsha, Hunan, China

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Chifeng Municipal Hospital

    Chifeng, Inner Mongolia, China

  • Affiliated Hospital of Inner Mongolia Medical University

    Hohhot, Inner Mongolia, China

  • The First People'S Hospital of Lianyungang

    Lianyungang, Jiangsu, China

  • Zhongda Hospital affiliated to Southeast University

    Nanjing, Jiangsu, China

  • Jiangnan University Medical Center

    Wuxi, Jiangsu, China

  • Xuzhou Medical University Affiliated Hospital

    Xuzhou, Jiangsu, China

  • Affiliated Hospital of Yangzhou Univrtsity

    Yangzhou, Jiangsu, China

  • Fengcheng People's Hospital

    Fengcheng, Jiangxi, China

  • Ganzhou People's Hospital

    Ganzhou, Jiangxi, China

  • The First Affiliated Hospital of NanChang University

    Nanchang, Jiangxi, China

  • ShangRao People's Hospital

    Shangrao, Jiangxi, China

  • China-Japan Union Hospital of Jilin University

    Changchun, Jilin, China

  • The first hospital of Jilin University

    Changchun, Jilin, China

  • Affiliated Zhongshan Hospital Of Dalian University

    Dalian, Jilin, China

  • China Medical University Affiliated Shengjing Hospital

    Shenyang, Liaoning, China

  • The Second Affiliated Hospital Of Xi'an Jiaotong University

    Xi'an, Shaanxi, China

  • The First Affiliated Hospital of Xi'an Jiao Tong University

    Xi'an, Shaanxi, China

  • Yan'an University Xianyang Hospital

    Xianyang, Shaanxi, China

  • Shandong Second Province General Hospital

    Jinan, Shandong, China

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.